Clinical Guide: Infantile Hypertrophic Pyloric Stenosis (IHPS)

1. Comprehensive Introduction & Overview

Infantile Hypertrophic Pyloric Stenosis (IHPS) is the most common cause of gastric outlet obstruction in infants, necessitating surgical intervention. It is characterized by the progressive hypertrophy and hyperplasia of the circular smooth muscle of the pylorus, leading to a functional obstruction of the gastric emptying process.

While the exact incidence varies globally, it is generally cited at 2 to 4 per 1,000 live births. There is a well-documented male predominance (approximately 4:1 ratio), and it is most frequently diagnosed in infants between 3 and 6 weeks of age. Early recognition is paramount to prevent the progression from mild emesis to severe metabolic derangement, specifically hypochloremic metabolic alkalosis.

2. Deep-Dive: Etiology and Pathophysiology

The Mechanisms of Hypertrophy

The pathogenesis of IHPS remains multifactorial, involving a complex interplay between genetic predisposition and environmental triggers.

• Genetic Factors: A significant familial clustering is observed. If a parent had IHPS, the risk to offspring is increased by 10–20 fold. It is associated with mutations in the NOS1 (neuronal nitric oxide synthase) gene, which regulates smooth muscle relaxation.
• Environmental Triggers: The administration of macrolide antibiotics (specifically erythromycin and azithromycin) in the first two weeks of life has been strongly linked to an increased risk of developing IHPS.
• Hormonal/Chemical Factors: Deficiencies in nitric oxide (NO) and insulin-like growth factor (IGF) have been implicated. NO is a critical inhibitory neurotransmitter in the gastrointestinal tract; its absence leads to uninhibited muscle contraction and subsequent hypertrophy.

Pathophysiological Progression

1. Muscle Proliferation: The pyloric muscle undergoes massive hypertrophy, creating a "pyloric tumor" that is palpable on physical examination.
2. Obstruction: As the muscle thickens, the pyloric canal narrows and elongates, creating a high-resistance orifice.
3. Gastric Distension: Inability to empty the stomach results in proximal gastric dilation and vigorous peristaltic waves (visible as "gastric waves").
4. Metabolic Derangement: Persistent non-bilious vomiting leads to the loss of hydrochloric acid. The body attempts to compensate by retaining bicarbonate, leading to a state of hypochloremic, hypokalemic metabolic alkalosis.

3. Clinical Presentation and Staging

Standard Presentation

The classic triad of IHPS includes:
* Non-bilious, projectile vomiting: Occurs shortly after feeding.
* Hungry infant: The infant remains hungry after vomiting and is eager to feed again.
* Palpable "Olive": A firm, mobile mass in the right upper quadrant or epigastrium, representing the hypertrophied pylorus.

Clinical Staging/Grading

While there is no formal "staging" system like cancer, clinicians categorize patients based on metabolic stability:

4. Differential Diagnosis

It is critical to differentiate IHPS from other causes of infant vomiting.

• Gastroesophageal Reflux (GERD): Usually presents with "spitting up" rather than forceful, projectile vomiting.
• Malrotation with Volvulus: Presents with bilious vomiting. This is a surgical emergency that requires immediate contrast studies.
• Pylorospasm: A functional disorder that mimics stenosis but lacks the anatomical hypertrophy seen on ultrasound.
• Adrenal Crisis (Congenital Adrenal Hyperplasia): Presents with vomiting and electrolyte abnormalities (hyponatremia and hyperkalemia), which is the inverse of IHPS lab findings.

5. Diagnostic Testing Protocols

Gold Standard: Ultrasonography (US)

Ultrasound is the diagnostic modality of choice due to its high sensitivity (95-100%) and lack of ionizing radiation.

Diagnostic Criteria for IHPS on Ultrasound:
* Pyloric Muscle Thickness: > 3.0 mm (The "gold" threshold).
* Pyloric Canal Length: > 15–17 mm.
* Target Sign: A cross-sectional view showing a thickened hypoechoic muscle ring around a hyperechoic central mucosa.

Laboratory Evaluation

• Complete Metabolic Panel (CMP): Essential to assess for hypochloremic metabolic alkalosis.
• Venous Blood Gas: Used to measure pH and bicarbonate levels to guide fluid resuscitation.

6. Risks, Management, and Contraindications

Surgical Management: Pyloromyotomy

The definitive treatment is a Ramstedt pyloromyotomy, which involves longitudinal incision of the pyloric muscle down to the mucosa, allowing the muscle to spread and the canal to open.

• Laparoscopic vs. Open: Laparoscopic pyloromyotomy is now the standard of care, offering reduced post-operative pain and faster recovery.
• Contraindications: Surgery should never be performed until metabolic stability is achieved. Operating on an infant with severe metabolic alkalosis significantly increases the risk of post-operative apnea.

Risks and Complications

• Mucosal Perforation: The most feared intraoperative complication. If recognized, it requires primary repair and a temporary delay in oral feeding.
• Incomplete Myotomy: Leads to persistent vomiting post-operatively, necessitating re-operation.
• Post-operative Emesis: Common in the first 24–48 hours due to gastric edema; does not necessarily indicate failure.

7. Massive FAQ Section

1. Is IHPS hereditary?

Yes, there is a strong genetic component. If a sibling or parent had IHPS, the infant is at a significantly higher risk.

2. Why is the vomiting "non-bilious"?

Because the obstruction occurs at the pylorus (the exit of the stomach), bile from the small intestine cannot reach the stomach.

3. Can IHPS be treated with medication?

Surgery is the standard of care. Atropine has been used in rare cases where surgery is contraindicated, but it requires prolonged hospitalization and has a high failure rate.

4. What happens if IHPS is left untreated?

The infant will progress to severe dehydration, malnutrition, metabolic failure, and eventually, shock and death.

5. Does the "olive" go away after surgery?

The pyloric muscle mass remains for several months post-operatively, but it will gradually remodel and shrink over time.

6. When can my baby feed after surgery?

Most surgeons initiate "ad lib" or structured oral feeding within 4–6 hours post-operatively.

7. Is there a link between macrolides and IHPS?

Yes. Exposure to erythromycin in the first two weeks of life is a well-established risk factor for developing IHPS.

8. What is the "Target Sign"?

It is the appearance of the pylorus on an ultrasound scan, where the thickened muscle appears as a dark ring (hypoechoic) surrounding the central, bright (hyperechoic) mucosa.

9. Can a baby have IHPS and GERD?

Yes, but they are distinct conditions. IHPS is an anatomical obstruction, whereas GERD is a functional relaxation of the lower esophageal sphincter.

10. What is the long-term prognosis?

Excellent. Once the pyloromyotomy is performed and recovery is complete, there are typically no long-term gastrointestinal sequelae. The infant should thrive and develop normally.

8. Clinical Summary Table

Disclaimer: This guide is intended for educational purposes for medical professionals and students. Clinical diagnosis and treatment decisions should always be made by a qualified pediatric surgeon or neonatologist based on individual patient assessment.